Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfil unmet medical needs in the gastrointestinal (GI) area. The team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities.
Albireo has Initiated a Clinical Study Using A3384 in Patients with Bile Acid Malabsorption
Inhibition of Intestinal Bile Acid Absorption by ASBT Inhibitor A4250 Protects Against Bile Acid-Mediated Cholestatic Liver Injury In Mice
Go to news archive
DDW, Chicago, May 2014